{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:43:09Z","timestamp":1697442189450},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,2,14]],"date-time":"2011-02-14T00:00:00Z","timestamp":1297641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Aim:\u2003<\/jats:bold> Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL) is a common cytogenetic abnormality associated with poor outcome in adults. This preliminary study, in the absence of substantial evidence, reported the prevalence of the BCR\u2010ABL gene fusion in ALL patients by RT\u2010PCR in Pakistan. Moreover, the prognostic significance of BCR\u2010ABL fusion along with other characteristics was also ascertained.<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold> One hundred forty six newly diagnosed ALL patients treated at our center between 2005 and 2008 comprised the study group. The patients were treated with a Children and Leukemia Group B induction regimen.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold> Among these patients, BCR\u2010ABL fusion oncogene was present in 43 of 78 patients (55%). A statistically significant difference in BCR\u2010ABL\u2010positivity within three age groups (&lt;20 years, 20\u201350 years, &gt;50 years) was observed (<jats:italic>P<\/jats:italic>= 0.001). The median age was significantly higher in the BCR\u2010ABL+ group (30 vs 19 years; <jats:italic>P<\/jats:italic>= 0.001). BCR\u2010ABL+ patients were also characterized by higher median WBC counts (96\u2003000\/\u00b5L vs 23\u2003000\/\/\u00b5L, <jats:italic>P<\/jats:italic>= 0.002). Complete remission was achieved in 74% BCR\u2010ABL\u2212 patients and 35% BCR\u2010ABL+ patients (<jats:italic>P<\/jats:italic>= 0.001). Only 10% of BCR\u2010ABL\u2212 patients achieved continued complete remission (CR). None of the BCR\u2010ABL+ patients maintained a CR further to induction therapy. With the available therapeutic protocol, the presence of a BCR\u2010ABL fusion predicted a lower survival (<jats:italic>P<\/jats:italic>= 0.001).<\/jats:p><jats:p><jats:bold>Conclusion:\u2003<\/jats:bold> A high prevalence of BCR\u2010ABL gene fusion was observed that appeared as a poor prognostic factor. Identification of this genetic entity at diagnosis is crucial for understanding the nature of adult ALL and for deciding optimal treatment.<\/jats:p>","DOI":"10.1111\/j.1743-7563.2010.01370.x","type":"journal-article","created":{"date-parts":[[2011,2,15]],"date-time":"2011-02-15T09:39:05Z","timestamp":1297762745000},"page":"47-55","source":"Crossref","is-referenced-by-count":3,"title":["High prevalence of <i>BCR\u2010ABL<\/i> fusion transcripts with poor prognostic impact among adult ALL patients: report from Pakistan"],"prefix":"10.1111","volume":"7","author":[{"given":"Mariam","family":"FAIZ","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qazi Javed","family":"IQBAL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif","family":"QURESHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,2,14]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"119","article-title":"Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome","volume":"40","author":"Thomas X","year":"1998","journal-title":"Hematol Cell Ther"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91706-Z"},{"key":"e_1_2_6_4_2","first-page":"1504","article-title":"Detection and significance of BCR\/ABL mRNA transcripts and fusion proteins in Philadelphia positive adult acute lymphoblastic leukemia","volume":"7","author":"Tuszynski A","year":"1993","journal-title":"Leukemia"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810133191506"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90049-3"},{"key":"e_1_2_6_7_2","first-page":"101","volume-title":"Acute Lymphoblastic Leukemia","author":"Bloomfield CD","year":"1990"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004063421402"},{"key":"e_1_2_6_9_2","first-page":"957","article-title":"Incidence and clinical outcome of children with BCR\/ABL\u2010positive acute lymphoblastic leukemia (ALL): a prospective RT\u2010PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL\u2010BFM 90 and CoALL\u2010 05\u201092","volume":"10","author":"Schlieben S","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.3.435.435"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17089-X"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950140317"},{"key":"e_1_2_6_13_2","first-page":"1211","article-title":"Prognostic implications of blast cell morphology in childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group","volume":"69","author":"Miller DR","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025"},{"key":"e_1_2_6_15_2","first-page":"156","article-title":"Single\u2010step method of RNA isolation by acid guanidinium thiocyanate\u2010phenol\u2010chloroform extraction","volume":"162","author":"Chomezynski P","year":"1987","journal-title":"Anal Biochem"},{"key":"e_1_2_6_16_2","first-page":"1254","article-title":"Multiplex\u2010polymerase chain assay for the detection of prognostically significant translocations in acute lymphoblastic leukemia","volume":"86","author":"Carolina M","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02983559"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(97)87415-2"},{"key":"e_1_2_6_19_2","first-page":"3983","article-title":"Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience","volume":"93","author":"Wetzler M","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_20_2","first-page":"3931","article-title":"Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia. Cancer and Leukemia Group B study 8364","volume":"93","author":"Czuczman MS","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_21_2","first-page":"3135","article-title":"Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique","volume":"87","author":"Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1990.8.6.994","article-title":"Results of the vincristine, doxorubicin and dexamethasone regimen in adults with acute lymphocytic leukemia","volume":"8","author":"Kantarjian HM","year":"1990","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.V86.4.1619.bloodjournal8641619","article-title":"Consolidation treatment of adult acute lymphoblastic leukemia: a prospective randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant Interleukin\u2010 2 after autologous bone marrow transplantation","volume":"86","author":"Attal M","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511471001"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-60377-8_103"},{"key":"e_1_2_6_26_2","first-page":"88","article-title":"Treatment of adult acute lymphoblastic leukemia: risk adapted strategies","volume":"12","author":"Stock W","year":"1999","journal-title":"Haematology"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.4226"},{"key":"e_1_2_6_28_2","first-page":"2588","article-title":"Single versus double autologous BMT\/PBSCT in patients with BCR\u2010ABL positive acute lymphoblastic leukemia","volume":"94","author":"Martin H","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22881"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1743-7563.2010.01370.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1743-7563.2010.01370.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T18:03:20Z","timestamp":1697393000000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1743-7563.2010.01370.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,14]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1111\/j.1743-7563.2010.01370.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1743-7563.2010.01370.x","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,14]]}}}